Pharming Group (PHGUF.PK) and Santarus Inc. (SNTS) Announce New Data From Open-Label Repeat Treatment Study With Rucomest
11/8/2013 9:08:34 AM
Pharming Group NV (NYSE
Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS) announced that new data from
an open-label extension of the pivotal Phase III clinical study with RUCONEST(®)
(recombinant human C1 esterase inhibitor, or rhC1INH) will be featured in a
poster presentation on November 9 & 10, 2013 at the 2013 American College of
Allergy, Asthma & Immunology Annual Scientific Meeting at the Convention Center
in Baltimore, Maryland. The poster is titled, Efficacy and Safety of
Recombinant Human C1 Esterase Inhibitor for Acute Attacks of Hereditary
Angioedema: An Open-Label Study.
Help employers find you! Check out all the jobs and post your resume.
comments powered by